Open AccessMeningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
Author(s) -
Francesco Facchinetti,
Antonin Lévy,
Samy Ammari,
Charles Naltet,
Pernelle Lavaud,
Mihaela Aldea,
Damien Vasseur,
David Planchard,
Benjamin Besse
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s292730
Subject(s) - ros1 , medicine , crizotinib , lung cancer , oncology , adenocarcinoma , pemetrexed , meningeal carcinomatosis , disease , cancer , chemotherapy , cisplatin , cerebrospinal fluid , malignant pleural effusion
ROS1 tyrosine kinase inhibitors (TKIs) have showed activity and efficacy in ROS1 -rearranged non-small cell lung cancer (NSCLC). In the clinical practice, besides the utilization of crizotinib, less is known about the best treatment strategies involving additional, new-generation TKIs for the sequential treatment of ROS1-positive NSCLC patients.